Waypoint Bio has closed a $20 million series A financing round to support its work developing next-generation in vivo CAR T therapeutics for solid tumors using a platform that integrates AI, computer vision and spatial pooled screening.
Laverock Therapeutics Ltd. has been awarded two new grants totaling in excess of £2.2 million (US$3 million) to support the next generation of its gene-control platform development, and expansion into additional nononcology therapeutics areas.
Chinese biotech Longbio Pharma Co. Ltd. announced its IPO on the Hong Kong Stock Exchange to raise HK$1.362 billion (US$174 million) to progress its lead candidate, LP-003, a next-generation anti-IgE antibody.
Biopharma and med-tech companies raising money in public or private financings, including: Assembly, Bleednfire, Clearnote Health, Kardigan, Protuoso, Q32, Reprogram.
Protuoso Biosciences has announced the close of an oversubscribed $9.5 million seed financing round, the proceeds of which will be used to advance its multifunctional protein engineering platform and broad pipeline across cardiometabolic, oncology and autoimmune diseases.
Reprogram Biosciences Inc., a preclinical oncology biotechnology company developing mRNA-based therapeutics to treat solid tumors, has announced the close of its seed financing, bringing the total capital raised to $6 million since the company’s founding in 2025.
Biopharma and med-tech companies raising money in public or private financings, including: Biostem, Cartesian, Editas, Hanchorbio, Kane, Mindmaze, Nanobiotix, Rani.
RSS
